Compound library / Fertility

GnRH Antagonists (Cetrotide / Ganirelix)

Injectable medications that prevent premature ovulation during IVF stimulation cycles by blocking the pituitary's LH surge.

CategoryFertility
Regulatory standingNo approved product cited
Typical routeSubcutaneous
Half-life~12-16 hours (Cetrotide), ~13-16 hours (Ganirelix)
Common dose range0.25 mg/day, started partway through stimulation per protocol
Typical cycle lengthSeveral days within an IVF stimulation cycle

BioHack Track models GnRH Antagonists (Cetrotide / Ganirelix) at a half-life of 14 hours, so every dose you log is decayed against that curve and the app shows estimated active levels — not just what you typed.

No approved product cited

No FDA-approved product for this compound is cited on this page, and no approved human dose is quoted. Treat the range below as research and community practice rather than a prescribed dose.

Reconstitution

Pre-filled syringes are common; some formulations require reconstitution with provided diluent.

Storage

Store at room temperature unless label specifies refrigeration.

Cautions

Timing within the IVF cycle is critical — always follow the fertility clinic's exact protocol and schedule.

Track GnRH Antagonists (Cetrotide / Ganirelix) in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.

Others in Fertility

Look up the research

These open a search of each database for GnRH Antagonists (Cetrotide / Ganirelix) — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.

Work it out

Where these figures come from

The half-life, route and dose range on this page are compiled from published pharmacokinetic literature, manufacturer and product monographs where one exists, and the ranges commonly reported in clinical and research use. They are kept as a range rather than a single figure because that is what the sources actually support — a half-life varies with route, formulation and the person.

These are not citations, and this page is not a review of the evidence. Where a number matters to you, follow the database links above and read the source. We say so plainly rather than dressing a compiled reference up as one.

Nothing on this page has been reviewed by a named clinician. It is a reference for people already tracking a protocol, not a recommendation to start one.

Published by Creative Images LLC · Last updated · Corrections: support